Labcorp Holdings Inc. (LH) is valued at $23 billion, offering comprehensive laboratory services globally. Its stock has fallen 2.7% from its 52-week high but has risen 5.4% in the past three months, outperforming the Health Care Select Sector SPDR Fund. LH stock is up 20.3% YTD and 24.2% over the past year, surpassing XLV’s performance.

Labcorp Holdings saw a 6.9% increase in shares after strong Q2 2025 results, with adjusted EPS of $4.35 and revenues of $3.53 billion. Diagnostics Laboratories grew 8.9% to $2.75 billion, and Biopharma Laboratory Services rose 11% to $784.8 million. Full-year 2025 guidance was raised, with revenue growth expected at 7.5% – 8.6% and adjusted EPS at $16.05 – $16.50.

Analysts remain bullish on Labcorp Holdings due to its outperformance relative to the sector. The stock has a consensus rating of “Strong Buy” from 18 analysts, with a mean price target of $295.53, a 5.9% premium to current levels. Quest Diagnostics (DGX) has outpaced LH on a YTD basis, surging 22.4%, but LH has performed better over the past year.

Read more at Yahoo Finance: Is LH Outperforming the Healthcare Sector?